Maria Kotowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Kotowska has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Piotr Albrecht
Department of Paediatric Gastroenterology and Nutrition, Medical University of Warsaw, Poland
10 shared publications - Agnieszka Gawrońska
Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
5 shared publications - Izabella Łazowska-Przeorek
Department of Pediatric Gastroenterology and Nutrition Medical University of Warsaw Warsaw Poland
5 shared publications - Katarzyna Karolewska-Bochenek
Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
5 shared publications Aleksandra Banaszkiewicz
Department of Paediatric Gastroenterology and Nutrition, Warsaw Medical University, Warsaw, Poland
4 shared publications- Andrzej Radzikowski
Department of Paediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland
4 shared publications
Latest Publications
- 19 November 2017
- Published by Springer Nature
- Vol. 1047, 81-87
A Two-Week Fecal Microbiota Transplantation Course in Pediatric Patients with Inflammatory Bowel Disease
Dysbiosis plays a major role in the etiology of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) is a new promising option for IBD treatment. We aimed to assess the effectiveness of a two-week FMT course in children with IBD. Ten patients, 10–17 years of age with moderate to severe IBD received a course of eight doses of freshly prepared FMT via a naso-duodenal tube or gastroscopy. All of the patients had pancolitis. There were eight cases of ulcerative colitis (UC) and two of Crohn’s disease (CD). Disease activity was evaluated using the Pediatric UC Activity Index (PUCAI) and Pediatric CD Activity Index (PCDAI) for UC and CD, respectively, CRP, and fecal calprotectin on the day before the first infusion and then on the day before the next course of FMT. Clinical response, defined as a decrease of 15 points in either index, was observed in 9/10 patients (seven UC and two CD). Clinical remission, defined as a PCDAI score ≤ 10 and PUCAI score < 10 measured at the same time point, was observed in 3/8 UC patients and 2/2 CD patients. Side effects observed were self-limiting and benign. We conclude that a short, intensive course of FMT has a beneficial effect on UC and CD colitis. FMT was well-tolerated and safe. Nonetheless, an optimal protocol of FMT administration is crucial for treatment efficacy.
- 19 November 2017
- Published by Springer Nature
- Vol. 1047, 81-87
A Two-Week Fecal Microbiota Transplantation Course in Pediatric Patients with Inflammatory Bowel Disease
Dysbiosis plays a major role in the etiology of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) is a new promising option for IBD treatment. We aimed to assess the effectiveness of a two-week FMT course in children with IBD. Ten patients, 10–17 years of age with moderate to severe IBD received a course of eight doses of freshly prepared FMT via a naso-duodenal tube or gastroscopy. All of the patients had pancolitis. There were eight cases of ulcerative colitis (UC) and two of Crohn’s disease (CD). Disease activity was evaluated using the Pediatric UC Activity Index (PUCAI) and Pediatric CD Activity Index (PCDAI) for UC and CD, respectively, CRP, and fecal calprotectin on the day before the first infusion and then on the day before the next course of FMT. Clinical response, defined as a decrease of 15 points in either index, was observed in 9/10 patients (seven UC and two CD). Clinical remission, defined as a PCDAI score ≤ 10 and PUCAI score < 10 measured at the same time point, was observed in 3/8 UC patients and 2/2 CD patients. Side effects observed were self-limiting and benign. We conclude that a short, intensive course of FMT has a beneficial effect on UC and CD colitis. FMT was well-tolerated and safe. Nonetheless, an optimal protocol of FMT administration is crucial for treatment efficacy.
- Open Access
- 1 January 2016
- Published by Polish Society of Microbiologists in Polish Journal of Microbiology
- Vol. 65 (1) , 89-91
Serotype-Specific Pneumococcal Status prior to PCV 13 Administration in Children and Adolescents with Inflammatory Bowel Disease
The aim of this study was to evaluate the serotype-specific pneumococcal status of children and adolescents with inflammatory bowel disease (IBD) who were naïve to pneumococcal vaccination before administering the 13-valent pneumococcal conjugate vaccine (PCV 13). This was an open, prospective study on children and adolescents aged 5–18 years who had IBD and were naïve to pneumococcal vaccination. A single dose of PCV 13 was administered to each patient. The geometric mean concentrations (GMCs) were measured for all 13 serotypes. A total of 122 subjects completed the study. Prevaccination GMCs ranged from 0.55 μg/ml (serotype 4) to 4.26 μg/ml (serotype 19A). Prior to the administration of PCV 13, high GMCs were detected in older children and adolescents who had IBD and were naïve to pneumococcal vaccination.
- 1 January 2016
- Published by Polish Society of Microbiologists in Polish Journal of Microbiology
- Vol. 65 (1) , 89-91
Open AccessSerotype-Specific Pneumococcal Status prior to PCV 13 Administration in Children and Adolescents with Inflammatory Bowel Disease
The aim of this study was to evaluate the serotype-specific pneumococcal status of children and adolescents with inflammatory bowel disease (IBD) who were naïve to pneumococcal vaccination before administering the 13-valent pneumococcal conjugate vaccine (PCV 13). This was an open, prospective study on children and adolescents aged 5–18 years who had IBD and were naïve to pneumococcal vaccination. A single dose of PCV 13 was administered to each patient. The geometric mean concentrations (GMCs) were measured for all 13 serotypes. A total of 122 subjects completed the study. Prevaccination GMCs ranged from 0.55 μg/ml (serotype 4) to 4.26 μg/ml (serotype 19A). Prior to the administration of PCV 13, high GMCs were detected in older children and adolescents who had IBD and were naïve to pneumococcal vaccination.
- 21 December 2015
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 32 (3) , 397-403
Indirect effects of a 7 year PCV7/PCV13 mass vaccination program in children on the incidence of pneumonia among adults: a comparative study based on two Polish cities
Background and objectives: In 2006 the city of Kielce, Poland, introduced a mandatory PCV7 (replaced by PCV13 in 2011) vaccination programme against S. pneumoanie for all children under 2 years old. At that time, the neighbouring city of Ostrowiec Świętokrzyski had no such large-scale vaccination programme in place. This created an opportunity to observe the results of the vaccination by comparing the incidence of pneumonia in these two cities. The aim of this study was to analyse how the incidence of pneumonia among adults were indirectly affected by the PCV7/PCV13 vaccintion programme in children during the seven-year follow-up period.Methods: We performed a retrospective study. PCV7/PCV13 vaccinations were delivered according to a 2+1 schedule. The vaccination rate in the analyzed period amounted to almost 99%.The following age groups were analysed: 30–49, 50–64 and 65+. The Cochran–Armitage test was used to investigate the significance of the observed trend in pneumonia morbidity. The signific...
- 21 December 2015
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 32 (3) , 397-403
Indirect effects of a 7 year PCV7/PCV13 mass vaccination program in children on the incidence of pneumonia among adults: a comparative study based on two Polish cities
Background and objectives: In 2006 the city of Kielce, Poland, introduced a mandatory PCV7 (replaced by PCV13 in 2011) vaccination programme against S. pneumoanie for all children under 2 years old. At that time, the neighbouring city of Ostrowiec Świętokrzyski had no such large-scale vaccination programme in place. This created an opportunity to observe the results of the vaccination by comparing the incidence of pneumonia in these two cities. The aim of this study was to analyse how the incidence of pneumonia among adults were indirectly affected by the PCV7/PCV13 vaccintion programme in children during the seven-year follow-up period.Methods: We performed a retrospective study. PCV7/PCV13 vaccinations were delivered according to a 2+1 schedule. The vaccination rate in the analyzed period amounted to almost 99%.The following age groups were analysed: 30–49, 50–64 and 65+. The Cochran–Armitage test was used to investigate the significance of the observed trend in pneumonia morbidity. The signific...
- 1 July 2015
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 21 (7) , 1607-1614
Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Pediatric Patients with Inflammatory Bowel Disease
There are only a few studies on immune response to pneumococcal vaccines in patients with inflammatory bowel disease (IBD); all of them assessed polysaccharide vaccines only. The aim of the study was to evaluate the immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) in IBD pediatric patients compared with healthy controls. This was a multicenter, prospective, and controlled study on children and adolescents aged 5 to 18 years with IBD with no history of pneumococcal immunization. The subjects for the study belonged to one of the following groups: patients with IBD on no immunosuppressive therapy (group A), those on tumor necrosis factor agents or immunomodulators (group B), and healthy controls (group C). The study population received 1 intramuscular injection of PCV13. The primary outcome measure was adequate vaccine response defined as postvaccination titer ≥0.35 μg/mL to all 13 serotypes. Geometric mean titers and geometric mean titer rises were measured for all serotypes. The evidence of local and systemic adverse effects for 5 days after the vaccine was registered. A total of 178 subjects (122 patients and 56 controls) completed the study course. There was no significant difference in the rate of adequate vaccine response between patients with IBD and controls measured 4 to 8 weeks after vaccination (90.4% versus 96.5%, P = 0.5281). Children in group A had higher geometric mean titer rises than children in group B (P = 0.0369). There were no serious adverse events related to PCV13 during the study. PCV13 is both immunogenic and safe in pediatric patients with IBD.
- 1 July 2015
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 21 (7) , 1607-1614
Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Pediatric Patients with Inflammatory Bowel Disease
There are only a few studies on immune response to pneumococcal vaccines in patients with inflammatory bowel disease (IBD); all of them assessed polysaccharide vaccines only. The aim of the study was to evaluate the immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) in IBD pediatric patients compared with healthy controls. This was a multicenter, prospective, and controlled study on children and adolescents aged 5 to 18 years with IBD with no history of pneumococcal immunization. The subjects for the study belonged to one of the following groups: patients with IBD on no immunosuppressive therapy (group A), those on tumor necrosis factor agents or immunomodulators (group B), and healthy controls (group C). The study population received 1 intramuscular injection of PCV13. The primary outcome measure was adequate vaccine response defined as postvaccination titer ≥0.35 μg/mL to all 13 serotypes. Geometric mean titers and geometric mean titer rises were measured for all serotypes. The evidence of local and systemic adverse effects for 5 days after the vaccine was registered. A total of 178 subjects (122 patients and 56 controls) completed the study course. There was no significant difference in the rate of adequate vaccine response between patients with IBD and controls measured 4 to 8 weeks after vaccination (90.4% versus 96.5%, P = 0.5281). Children in group A had higher geometric mean titer rises than children in group B (P = 0.0369). There were no serious adverse events related to PCV13 during the study. PCV13 is both immunogenic and safe in pediatric patients with IBD.
- Open Access
- 1 January 2015
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 21, 1827-1830
Value of Antral Nodularity for the Diagnosis of Helicobacter pylori Infection in Children
BACKGROUND:The aim of this study was to confirm the role of antral nodularity in the diagnosis of Helicobacter pylori (H. pylori) infection in children. MATERIAL AND METHODS:This prospective study included 107 children (58 male; 54.2%), between the a...
- 1 January 2015
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 21, 1827-1830
Open AccessValue of Antral Nodularity for the Diagnosis of Helicobacter pylori Infection in Children
BACKGROUND:The aim of this study was to confirm the role of antral nodularity in the diagnosis of Helicobacter pylori (H. pylori) infection in children. MATERIAL AND METHODS:This prospective study included 107 children (58 male; 54.2%), between the a...
- 1 July 2011
- Published by Elsevier in The Journal of Pediatrics
- Vol. 159 (1) , 45-49
Sequential Therapy Compared with Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Double-Blind, Randomized, Controlled Trial
- 1 July 2011
- Published by Elsevier in The Journal of Pediatrics
- Vol. 159 (1) , 45-49
Sequential Therapy Compared with Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Double-Blind, Randomized, Controlled Trial
- 30 June 2011
- Published by Termedia Sp. z.o.o. in Pediatria Polska
- Vol. 86 (3) , 270-275
Dotychczasowe doświadczenia i obserwacje ze szczepieniami za pomocą skoniugowanych szczepionek przeciwpneumokokowych w schemacie 2+1
- 30 June 2011
- Published by Termedia Sp. z.o.o. in Pediatria Polska
- Vol. 86 (3) , 270-275
Dotychczasowe doświadczenia i obserwacje ze szczepieniami za pomocą skoniugowanych szczepionek przeciwpneumokokowych w schemacie 2+1
- 1 May 2011
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (5) , 1117-1124
Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease
There are only a few studies on immune response to routine vaccinations in children with inflammatory bowel disease (IBD), despite a strong need for this kind of study. The aim of the study was to evaluate the immunogenicity of an inactivated hepatitis A vaccine (HAV) in IBD pediatric patients compared with healthy controls. This was an open, prospective, and controlled study on anti-HAV-negative children and adolescents age 2-18 years with IBD. HAV using 720 enzyme-linked immunosorbent assay (ELISA) units were administered at 0 months and at 6-12 months. Seroconversion and geometric mean titers were measured after each vaccine dose. The evidence of local and systemic adverse effects for 3 days after the first and second dose of vaccine was registered. A total of 134 subjects (66 patients and 68 controls) completed the whole study course consisting of two doses of vaccine and six serum samples. There was no significant difference in the rate of seroconversion between IBD patients and controls when measured after the second dose of vaccine (97% versus 100%, P = 0.2407), but the rate was significantly lower in the IBD group when measured after the first dose (39% versus 64%, P = 0.00001). The mean geometric titers were statistically significantly lower in the IBD group than in the control group at all of the measured timepoints. There were no serious adverse events related to HAV during the study. HAV is both immunogenic and safe in pediatric patients with IBD.
- 1 May 2011
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (5) , 1117-1124
Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease
There are only a few studies on immune response to routine vaccinations in children with inflammatory bowel disease (IBD), despite a strong need for this kind of study. The aim of the study was to evaluate the immunogenicity of an inactivated hepatitis A vaccine (HAV) in IBD pediatric patients compared with healthy controls. This was an open, prospective, and controlled study on anti-HAV-negative children and adolescents age 2-18 years with IBD. HAV using 720 enzyme-linked immunosorbent assay (ELISA) units were administered at 0 months and at 6-12 months. Seroconversion and geometric mean titers were measured after each vaccine dose. The evidence of local and systemic adverse effects for 3 days after the first and second dose of vaccine was registered. A total of 134 subjects (66 patients and 68 controls) completed the whole study course consisting of two doses of vaccine and six serum samples. There was no significant difference in the rate of seroconversion between IBD patients and controls when measured after the second dose of vaccine (97% versus 100%, P = 0.2407), but the rate was significantly lower in the IBD group when measured after the first dose (39% versus 64%, P = 0.00001). The mean geometric titers were statistically significantly lower in the IBD group than in the control group at all of the measured timepoints. There were no serious adverse events related to HAV during the study. HAV is both immunogenic and safe in pediatric patients with IBD.
- Open Access
- 9 June 2005
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 21 (12) , 1509
Saccharomyces boulardii and antibiotic-associated diarrhoea in children: Author's reply
- 9 June 2005
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 21 (12) , 1509
Open AccessSaccharomyces boulardii and antibiotic-associated diarrhoea in children: Author's reply